Product Details
| Product Name:
Pamiparib |
CAS No.:
1446261-44-4 |
| Purity:
99.69% |
Supply Ability:
10g |
| Release date:
2025/07/30 |
Product Introduction
Bioactivity
| Name | Pamiparib |
| Description | Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor with IC50 values of 0.9 nM for PARP1 and 0.5 nM for PARP2. It exhibits strong PARP trapping, has the capability to penetrate the brain, and is used for researching various cancers, including solid tumors. |
| In vivo | Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD).?Pamiparib has good bioavailability and is 16-fold more potent than olaparib in an efficacy study using BRCA1 mutated MDA-MB-436 breast cancer xenograft model.?Pamiparib also shows strong anti-tumor synergy with temozolomide (TMZ), a DNA alkylating agent used to treat brain tumors.?Compared to other PARP inhibitors, pamiparib demonstrated improved penetration across the blood brain barrier (BBB) in mice.?Oral administration of pamiparib at a dose as low as 3 mg/kg is sufficient to abrogate PARylation in brain tumor tissues.?In SCLC-derived, TMZ-resistant H209 intracranial xenograft model, combination of pamiparib with TMZ overcomes its resistance and shows significant tumor inhibitory effects and prolonged life span[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 62.5 mg/mL (209.51 mM), Sonication is recommended.
|
| Keywords | poly ADP ribose polymerase | PARP2 | PARP1 | PARP | Pamiparib | Inhibitor | inhibit | BGB290 | BGB 290 |
| Inhibitors Related | 4'-Methoxychalcone | Niraparib tosylate monohyrate | VPC-70063 | 3-Aminobenzamide | XAV-939 | Niraparib | 3-Methoxybenzamide | NU1025 | Olaparib | Benzamide | Picolinamide | OUL35 |
| Related Compound Libraries | Highly Selective Inhibitor Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:57-63-6
$32.00 / 100mg
-
CAS:1630743-73-5
$0.00 / 5mg
-
CAS:54639-48-4
$32.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$2980.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-20 |
United States